Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,683,500
New position
Shares Held
150,000
first reported quarter
Ownership
0.271%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Driehaus Capital Management LLC holds $3,010,622,183 across 56 Biotechnology names. AKTS ranks #53 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PRAX |
Praxis Precision Medicines, Inc.
|
949,225 | $305,830,802 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
4,491,653 | $261,189,621 | |
| 3 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
6,395,922 | $232,299,887 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
1,920,800 | $161,673,736 | |
| 5 | EWTX |
Edgewise Therapeutics, Inc.
|
4,477,942 | $141,055,173 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
2,790,785 | $140,767,195 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
5,911,889 | $111,734,702 | |
| 8 | SEPN |
Septerna, Inc.
|
4,395,572 | $105,625,595 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,683,500 | 150,000 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||